Methods for treating autism spectrum disorder and associated symptoms
The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
1. A method for treating an autism spectrum disorder (ASD) or a gastrointestinal symptom associated with ASD in a subject in need thereof, the method comprising orally administering to the subject (i) a pharmaceutical composition comprising a community of fecal bacteria from a stool of a human donor, wherein the community of fecal bacteria has been derived without selection from the stool; and (ii) a bacterial isolate comprising bacteria of the genus Lactobacillus.
2. The method of claim 1 , wherein the bacterial isolate is not derived from the stool of the human donor.
3. The method of claim 1 , wherein the pharmaceutical composition comprises the bacterial isolate.
4. The method of claim 1 , wherein the pharmaceutical composition and the bacterial isolate are formulated together in a geltab, pill, microcapsule, capsule, or tablet.
5. The method of claim 1 , wherein the pharmaceutical composition and the bacterial isolate are administered separately to the subject.
6. The method of claim 5 , wherein the pharmaceutical composition comprises a geltab, pill, microcapsule, capsule, or tablet.
7. The method of claim 5 , wherein the bacterial isolate is formulated in a geltab, pill, microcapsule, capsule, or tablet.
8. The method of claim 1 , wherein the method further comprises pretreating the subject with an antibiotic.
9. The method of claim 1 , wherein the subject is a human below the age of 18.
10. The method of claim 1 , wherein the subject is a human adult.
11. The method of claim 1 , wherein the ASD is selected from the group consisting of: autistic disorder, pervasive developmental disorder not otherwise specified (PDD-NOS), and Asperger syndrome.
12. The method of claim 1 , wherein the treating comprises a reduction in severity of a symptom of the ASD selected from the group consisting of: irritability, agitation, lethargy, social withdrawal, stereotypic behavior, hyperactivity, noncompliance, inappropriate speech, and a combination thereof.
13. The method of claim 12 , wherein the subject exhibits at least a 10% reduction in severity of the symptom as a result of the treating.
14. The method of claim 13 , wherein the reduction in severity of the symptom is based on an assessment system selected from the group consisting of: Childhood Autism Rating Scale (CARS), Childhood Autism Rating Scale 2-Standard Form (CARS2-ST), Childhood Autism Rating Scale 2-High Functioning (CARS2-HF), and a combination thereof.
15. The method of claim 1 , wherein the subject exhibits one or more gastrointestinal symptoms selected from the group consisting of: abdominal pain, reflux, indigestion, irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.
16. The method of claim 15 , wherein the one or more gastrointestinal symptoms is constipation.
17. A method for treating an autism spectrum disorder (ASD) or a gastrointestinal symptom associated with ASD in a subject in need thereof, the method comprising orally administering to the subject a pharmaceutical composition comprising (i) a community of fecal bacteria extracted from a stool of a human donor, wherein the community of fecal bacteria has been derived without selection from the stool; and (ii) cultured bacteria comprising bacteria of the genus Lactobacillus.
18. The method of claim 17 , wherein the pharmaceutical composition is formulated as a geltab, pill, microcapsule, capsule, or tablet.
19. The method of claim 17 , wherein the method further comprises pretreating the subject with an antibiotic.
20. The method of claim 17 , wherein the subject is a human below the age of 18.
21. The method of claim 17 , wherein the subject is a human adult.
22. The method of claim 17 , wherein the ASD is selected from the group consisting of: autistic disorder, pervasive developmental disorder not otherwise specified (PDD-NOS), and Asperger syndrome.
23. The method of claim 17 , wherein the treating comprises a reduction in severity of a symptom of the ASD selected from the group consisting of: irritability, agitation, lethargy, social withdrawal, stereotypic behavior, hyperactivity, noncompliance, inappropriate speech, and a combination thereof.
24. The method of claim 23 , wherein the reduction in the severity of the symptom is based on an assessment system selected from the group consisting of: Childhood Autism Rating Scale (CARS), Childhood Autism Rating Scale 2-Standard Form (CARS2-ST), Childhood Autism Rating Scale 2-High Functioning (CARS2-HF), and a combination thereof.
25. The method of claim 17 , wherein the subject exhibits one or more gastrointestinal symptoms selected from the group consisting of: abdominal pain, reflux, indigestion, irritable bowel syndrome, chronic persistent diarrhoea, diarrhoea, flatulence, constipation, and alternating constipation/diarrhoea.
26. The method of claim 25 , wherein the one or more gastrointestinal symptoms is constipation.